Atopic Dermatitis Plasma
Powered by BiozAbout:Atopic Dermatitis Plasma — cryopreserved human plasma from consented donors with clinically confirmed atopic dermatitis, processed within one day of collection. Suited to type 2 mediator profiling including CCL17/TARC, IL-13 and IL-31, and to proteomic and metabolomic biomarker discovery. Donors can be stratified by EASI or SCORAD severity, blood eosinophil count, and biologic treatment status.
About Atopic Dermatitis Plasma
Atopic Dermatitis Plasma for Type 2 Inflammation and Skin Barrier Research
Atopic Dermatitis Plasma is collected from IRB-consented donors clinically diagnosed with atopic dermatitis, a chronic form of eczema, and processed within one day of collection to preserve cytokines, chemokines, proteins, and metabolites. Atopic dermatitis is an allergic, type 2-skewed inflammatory disease in which epidermal barrier dysfunction and a Th2-dominated immune response reinforce each other; it is not an autoantibody-driven condition. Plasma from these donors supports research into circulating type 2 mediators, barrier biology, and treatment response.
Why Plasma for Atopic Dermatitis Research
- The core cytokines of atopic dermatitis — IL-4, IL-13, IL-5 and IL-31 — are the direct targets of dupilumab, tralokinumab, nemolizumab and the JAK inhibitor class. Plasma is the accessible matrix for measuring the soluble output of that axis and for pharmacodynamic work.
- CCL17 (TARC) is among the best-replicated circulating correlates of atopic dermatitis severity, and CCL22, periostin and TSLP-associated markers are studied alongside it. All are measurable in plasma.
- Barrier dysfunction is central to the disease. Filaggrin loss-of-function variants are the strongest established genetic risk factor, and plasma from genotyped donors allows soluble inflammatory readouts to be interpreted against barrier genotype.
- Total IgE and eosinophil-associated mediators reflect the type 2 skew and the atopic comorbidity burden — asthma, allergic rhinitis and food allergy — that frequently accompanies atopic dermatitis.
- Plasma avoids the ex vivo platelet degranulation that occurs during clotting, which matters when measuring platelet-stored chemokines such as CXCL4 and CCL5 that would otherwise be artefactually elevated in serum.
- Plasma drawn alongside a skin punch biopsy or PBMCs from the same donor lets circulating mediators be tied to lesional tissue and to the responsible cell populations.
Donor Stratification Available
- Disease severity by EASI, SCORAD or Investigator Global Assessment where recorded
- Body surface area involvement and affected sites
- Total IgE level and blood eosinophil count where available
- Treatment status: topical-only, biologic-naive, on dupilumab or other type 2 biologic, on JAK inhibitor, on systemic immunosuppressant, or in washout
- Atopic comorbidity: asthma, allergic rhinitis, food allergy, or atopic dermatitis alone
- Age group, including paediatric and adult donors
- Matched healthy controls available
Product Features
- Research Use Only (RUO)
- Plasma collected from clinically confirmed atopic dermatitis donors
- Processed within one day of collection
- Anticoagulant selection available on request
- IRB-approved protocols and informed consent
- Custom aliquot volumes available upon request
De-identified Donor Data
- Verified atopic dermatitis diagnosis
- Demographic data: age, sex assigned at birth, race/ethnicity
- Donor-reported medications, allergies, and comorbidities
- Disease severity and treatment history where available
- Additional atopic dermatitis-specific metadata available on request
- Explore our Atopic Dermatitis Donor Network
Applications
- Type 2 cytokine and chemokine multiplex profiling, including CCL17/TARC
- Pharmacodynamic and target-engagement studies for IL-4R, IL-13 and IL-31 directed therapeutics
- Biomarker discovery and validation for disease severity and flare prediction
- Proteomic profiling of systemic type 2 inflammation
- Metabolomic and lipidomic studies of barrier lipid metabolism
- Itch pathway research focused on IL-31 and related mediators
- Assay development and validation using disease-state plasma as a clinically relevant matrix
- Comparative profiling of atopic dermatitis against psoriasis and other inflammatory skin disease
Other Atopic Dermatitis Specimen Types
- Atopic Dermatitis Serum
- Atopic Dermatitis Whole Blood
- Atopic Dermatitis PBMC
- Atopic Dermatitis Leukopak
- Atopic Dermatitis Skin Punch Biopsy
- Atopic Dermatitis Bulk Plasma
Compliance and Quality Assurance
- IRB-approved and HIPAA-compliant protocols
- Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
- Documentation support available for regulatory review
Ordering & Customization
Atopic dermatitis plasma is available in standard and custom volumes. For pricing, availability, or to discuss a severity-stratified cohort, email learnmore@sanguinebio.com. For international orders or documentation requirements, please contact us to ensure compatibility with your country’s regulations. To browse plasma across all disease states and healthy donors, visit our human plasma page.
Applications
- Immunology and translational research
- Biomarker discovery and validation
- Drug screening and assay development
- Vaccine and infectious disease research
Product Features
- Research Use Only (RUO), Plasma
- Sourced from screened, consented donors
- Processed under validated SOPs
- QC tested for purity, viability, and sterility
- Processed within 24 hours of collection
- IRB-approved protocols with electronic informed consent
Donor Metadata
- Verified diagnosis and clinical history
- Demographic data: age, sex assigned at birth, race/ethnicity
- Medication and treatment background when available
Compliance and Quality Assurance
- IRB-approved collections and standardized procedures
- 21 CFR Part 11-compliant e-consent system
- HIPAA-compliant data management
Ordering & Customization
Human Plasma are available in customizable aliquot sizes. For international orders or documentation needs, please contact learnmore@sanguinebio.com to confirm requirements and availability. We also work with multiple ordering platforms and distributors, learn more here.
Protocols & Documentation
-
Download
Plasma Isolation
Protocol for plasma separation from anticoagulated whole blood, including processing, storage, and traceability requirements.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Plasma
Where can I find your complete catalog?
You can find our full product catalog here.
How long can samples be stored?
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
What customization options are available?
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
Do you offer prospective collections?
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
What is the turnaround time for custom collections?
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
Do you have samples in stock?
YES - we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
What does unique donor mean?
Each sample from a different individual - Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
Are samples collected under IRB-approved protocols?
YES - "IRB-approved collection protocols" and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Frequently Asked Questions
Ask a Question
Pair with a Healthy Control
Match your Atopic Dermatitis Plasma with normal donor samples for comparison
Healthy Plasma
206 In Stock View InventoryNeed a custom Plasma cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.